Clinical trials: Polycythemia, Primary
Polycythemia Vera
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera.
- Trial name
- NCT05269771
- Testing
- Ruxolitinib
- Where
- 25 sites in Australia, Belgium and 6 more
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloproliferative Neoplasms
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
This is a multicenter, open label, long-term study testing the long-term safety, tolerability and efficacy of givinostat in patients with Polycythemia Vera, Essential Thrombocythemia, primary Myelofibrosis, Post-Polycythemia Vera…
- Trial name
- NCT01761968
- Testing
- givinostat
- Where
- 15 sites in Germany, Italy and 1 more
- Volunteers
- 90 people
- Sponsor
- Italfarmaco
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Polycythemia Vera
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
- Trial name
- GIV-IN-PV (NCT06093672)
- Testing
- Givinostat, Hydroxyurea
- Where
- 90 sites in United States, Austria and 14 more
- Volunteers
- 220 people
- Sponsor
- Italfarmaco
Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic…
- Conditions
- Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT06063486
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Southern California
Essential Thrombocythemia, Polycythemia Vera
Efficacy and Safety of Peginterferon in ET and PV.
This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).
- Trial name
- NCT06734637
- Testing
- Peginterferon α-2b injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhenya Hong
MPN (Myeloproliferative Neoplasms)
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
- Trial name
- NCT01633372
- Testing
- itacitinib
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 87 people
- Sponsor
- Incyte Corporation
Polycythemia Vera, Essential Thrombocythemia
A Study of GLB-001 in Patients With Myeloid Malignancies
Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or…
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
- Trial name
- NCT06378437
- Testing
- GLB-001
- Where
- 14 sites in China
- Volunteers
- 108 people
- Sponsor
- Hangzhou GluBio Pharmaceutical Co., Ltd.
Polycythemia Vera
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
Polycythemia vera (PV) is a rare blood cancer in which the body makes too many red blood cells. This can make the blood thicker and may increase the risk of serious health problems such as blood clots.
- Trial name
- NCT07648030
- Testing
- Rusfertide
- Where
- 9 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Takeda
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Myelofibrosis, Essential Thrombocythemia
CEP-701 (Lestaurtinib) in Myelofibrosis
Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are produced) by fibrous tissue which reduces the body's ability to produce new blood cells and results in the development of chronic…
- Conditions
- Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT00668421
- Testing
- CEP-701 (Lestaurtinib)
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ronald Hoffman
Myeloproliferative Diseases
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
The goal of this clinical research study is to learn if giving pacritinib before standard of care drugs followed by an allogeneic stem cell transplant can help to control myeloproliferative neoplasms.
- Trial name
- NCT02410551
- Testing
- Pacritinib, Busulfan, Questionnaires
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF)
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
The primary objective of this study is to evaluate the efficacy of INC424 in patients with PMF, PPV MF, or PET-MF using a composite measure of either an objective endpoint (> 50% reduction in splenomegaly using palpitation at 48…
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
- Trial name
- MACS2030 (NCT01558739)
- Testing
- INC424
- Where
- 10 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis (PMF)
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.
- Conditions
- Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04676529
- Testing
- PXS-5505
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 43 people
- Sponsor
- Syntara
Myeloproliferative Neoplasms of, Polycythemia Vera
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms.
- Conditions
- Myeloproliferative Neoplasms of, Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Trial name
- NCT01520220
- Testing
- LY2784544
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Polycythemia Vera, Essential Thrombocytosis
Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
The three main chronic myeloproliferative disorders are polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).
- Conditions
- Polycythemia Vera, Essential Thrombocytosis, Idiopathic Myelofibrosis, Neutrophils
- Trial name
- NCT00433862
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF)…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera
- Trial name
- NCT02124746
- Testing
- Momelotinib
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 87 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Polycythemia Vera
Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis.
- Trial name
- Prospero (NCT05548062)
- Testing
- Hydroxyurea, Ruxolitinib
- Where
- 33 sites in Italy
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Polycythemia Vera
LOW-PV Continuation
This multicenter longitudinal observational study focuses on Italian patients with Polycythemia Vera (PV) who were enrolled in the Low-PV RCT and continued receiving Ropeginterferon alfa-2b until the study's conclusion on March…
- Trial name
- CONT-LOW-PV (NCT06752941)
- Where
- 13 sites in Italy
- Volunteers
- 36 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS